Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
1 evidence topic · 1 source
STELLAR-303 investigational dosing and administration
| Trial arm | Direct quotation |
|---|---|
| Zanzalintinib plus atezolizumab | “XL092 100 mg PO QD + atezolizumab 1200 mg IV Q3W” |
| Regorafenib | “regorafenib 160 mg PO QD (21 days/28-day cycle)” |